IVA [NASD]
Inventiva S.A.
Index- P/E- EPS (ttm)-1.33 Insider Own- Shs Outstand40.87M Perf Week-5.11%
Market Cap164.13M Forward P/E- EPS next Y- Insider Trans- Shs Float- Perf Month-22.40%
Income- PEG- EPS next Q- Inst Own24.68% Short Float- Perf Quarter-45.30%
Sales- P/S- EPS this Y- Inst Trans- Short Ratio18.56 Perf Half Y-63.75%
Book/sh2.17 P/B1.75 EPS next Y- ROA- Target Price18.61 Perf Year-72.29%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range3.75 - 15.78 Perf YTD-72.11%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-75.98% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low1.07% ATR0.28
Employees101 Current Ratio- Sales Q/Q- Oper. Margin- RSI (14)32.55 Volatility9.60% 5.80%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume1.01 Prev Close3.81
ShortableYes LT Debt/Eq- EarningsSep 21 AMC Payout- Avg Volume7.39K Price3.79
Recom- SMA20-7.41% SMA50-18.04% SMA200-59.60% Volume1,556 Change-0.52%
Mar-08-21Downgrade Societe Generale Buy → Sell
Aug-05-20Initiated ROTH Capital Buy
Aug-04-20Initiated Stifel Buy $18
Aug-04-20Initiated Guggenheim Buy $26
Sep-26-22 01:37PM
Sep-22-22 07:27AM
02:30AM
Sep-21-22 04:40PM
Sep-08-22 09:35AM
Sep-07-22 04:00PM
Jul-28-22 04:00PM
Jul-21-22 12:00PM
Jul-07-22 04:00PM
Jul-04-22 12:45PM
Jun-16-22 04:00PM
Jun-15-22 09:55AM
Jun-09-22 04:00PM
Jun-07-22 04:00PM
Jun-03-22 04:00PM
May-23-22 04:00PM
May-20-22 04:00PM
May-19-22 04:00PM
May-16-22 04:00PM
12:24PM
02:00AM
Apr-28-22 10:35AM
10:30AM
Apr-07-22 04:00PM
Apr-05-22 10:45AM
Mar-11-22 04:44PM
Mar-08-22 02:00AM
Mar-07-22 04:27PM
Mar-01-22 04:00PM
Feb-28-22 04:00PM
Feb-23-22 10:00AM
Feb-14-22 04:00PM
Jan-31-22 04:00PM
Jan-20-22 04:00PM
Jan-14-22 02:00AM
Dec-16-21 04:00PM
Dec-06-21 04:00PM
Nov-10-21 04:00PM
Nov-03-21 04:00PM
Oct-29-21 09:29AM
Oct-28-21 07:15AM
Oct-27-21 04:00PM
Oct-18-21 04:00PM
Sep-28-21 04:00PM
Sep-23-21 02:45AM
Sep-22-21 07:01AM
Sep-21-21 04:00PM
Sep-20-21 04:10PM
Sep-16-21 04:00PM
Sep-10-21 09:00AM
Sep-08-21 04:00PM
Aug-30-21 04:00PM
Aug-02-21 05:00PM
Jul-28-21 04:00PM
Jul-22-21 10:00AM
Jun-15-21 04:00PM
Jun-09-21 04:00PM
May-25-21 04:00PM
May-12-21 04:00PM
Apr-26-21 04:00PM
Apr-19-21 04:00PM
12:00PM
Mar-25-21 01:00PM
10:43AM
Mar-15-21 05:00PM
Mar-05-21 11:45AM
Mar-04-21 04:00PM
Feb-25-21 04:00PM
Feb-24-21 04:00PM
Feb-23-21 04:00PM
Feb-11-21 04:00PM
Jan-15-21 11:45AM
Jan-06-21 04:00PM
Jan-05-21 04:00PM
Dec-07-20 11:18PM
04:00PM
Nov-24-20 04:00PM
Nov-12-20 04:00PM
Nov-10-20 04:00PM
Nov-09-20 04:00PM
Nov-05-20 04:00PM
Nov-02-20 04:00PM
02:00AM
Oct-28-20 05:00PM
Oct-19-20 04:00PM
Oct-12-20 04:00PM
Oct-05-20 04:00PM
Sep-24-20 12:15PM
Sep-17-20 06:00AM
Sep-16-20 04:00PM
Sep-09-20 11:45AM
Aug-12-20 11:45AM
Aug-10-20 11:45AM
Jul-24-20 06:12PM
Jul-15-20 02:40PM
Jul-10-20 08:30AM
02:00AM
02:00AM
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of MPS VI subtype disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company has strategic collaboration with AbbVie for the treatment of autoimmune diseases; and Boehringer Ingelheim International GmbH for developing new treatments for idiopathic pulmonary fibrosis. Inventiva S.A. was founded in 2011 and is based in Daix, France.